Skip to main content
SpringerLink
Log in

Cancer Immunotherapy at the Crossroads

How Tumors Evade Immunity and What Can Be Done

  • Book
  • © 2004

Overview

Editors:
  1. James H. Finke

    1. Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Ronald M. Bukowski

    1. Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Current Clinical Oncology (CCO)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (19 chapters)

  1. Front Matter

    Pages i-xvii
    Download chapter PDF

  2. Basic Mechanisms of Immune Evasion

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. HLA Class I Antigen-Processing Machinery and HLA Class I Antigen-Derived Peptide-Complex Defects in Tumor-Cell Escape

      • Michael Campoli, Chien-Chung Chang, Xin-Hui Wang, Soldano Ferrone
      Pages 3-34

    3. Immune Defects in T Cells From Cancer Patients

      • Augusto C. Ochoa, Paulo C. Rodriguez, Jovanny Zabaleta, Pelayo Correa, Arnold H. Zea
      Pages 35-48

    4. Malfunction of the Dendritic Cell System in Cancer

      • Zoya R. Yurkovetsky, Irina L. Tourkova, Levent Balkir, Lori Perez, Galina V. Shurin, Gurkamal S. Chatta et al.
      Pages 49-65

    5. CD4+ T-Cell-Mediated Immunity to Cancer

      • Tomohide Tatsumi, Amy Wesa, James H. Finke, Ronald M. Bukowski, Walter J. Storkus
      Pages 67-86

    6. Immunological Ignorance in Cancer

      • Koji Tamada, Lieping Chen
      Pages 87-99

    7. The Role of Receptor-Mediated Apoptosis in T-Cell Dysfunction

      • Hannah Rabinowich, Brian R. Gastman
      Pages 101-117

    8. Alterations in T-Cell Signaling Pathways and Increased Sensitivity to Apoptosis

      • Ithaar H. Derweesh, Luis Molto, Charles Tannenbaum, Patricia Rayman, Christina Moon, Cynthia Combs et al.
      Pages 119-144

    9. The Role of Tumor Gangliosides in the Immune Dysfunction of Cancer

      • Stephan Ladisch
      Pages 145-156

    10. Interleukin-10-Induced Immune Suppression in Cancer

      • Arvin S. Yang, Edmund C. Lattime
      Pages 157-172

    11. Accentuating Tumor Immunity Through Costimulation

      • Andrew D. Weinberg, Dean E. Evans, Arthur A. Hurwitz
      Pages 173-194

    12. Optimizing T-Cell Adoptive Immunotherapy to Overcome Tumor Evasion

      • Peter A. Cohen, Gregory E. Plautz, James H. Finke, Suyu Shu
      Pages 195-213

    13. Tumor Resistance to Apoptosis

      • Robert G. Uzzo, Paul Cairns, Nickolai Dulin, Eric M. Horwitz, Alan Pollack, Vladimir Kolenko
      Pages 215-234

  3. Clinical Relevance of Immune Evasion

    1. Front Matter

      Pages 235-235
      Download chapter PDF

    2. The Development and Reversal of T-Cell Tolerance in Cancer Patients Receiving Peptide-Based Vaccines

      • Ena Wang, Francesco M. Marincola
      Pages 237-255

    3. Altered Signaling in T Lymphocytes of Patients With Cancer

      • Theresa L. Whiteside
      Pages 257-277

    4. Allogeneic Hematopoietic Blood-Cell Transplantation As Immunotherapy for Metastatic Renal Cell Carcinoma

      • Richard W. Childs, Cristian A. Carvallo
      Pages 279-293

    5. Immune Defects in Patients Suffering From Non-Hodgkin’s Lymphoma

      • Thomas Zander, Daniel Re, Michael von Bergwelt-Baildon, Jürgen Wolf, Joachim L. Schultze
      Pages 295-314

    6. Immune Dysfunction in Classical Hodgkin’s Lymphoma

      • Arjan Diepstra, Ewerton M. Maggio, Anke van den Berg, Sibrand Poppema
      Pages 315-334
Back to top

Keywords

About this book

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Reviews

"...good reading for all those interested in oncological immunotherapy." -Cancer Forum

"State of the art and insightful...illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors." - Tumori

Editors and Affiliations

  • Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, USA

    James H. Finke

  • Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, USA

    Ronald M. Bukowski

Bibliographic Information

  • Book Title: Cancer Immunotherapy at the Crossroads

  • Book Subtitle: How Tumors Evade Immunity and What Can Be Done

  • Editors: James H. Finke, Ronald M. Bukowski

  • Series Title: Current Clinical Oncology

  • DOI: https://doi.org/10.1007/978-1-59259-743-7

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2004

  • Hardcover ISBN: 978-1-58829-183-7Published: 24 November 2003

  • Softcover ISBN: 978-1-4684-9844-8Published: 02 August 2012

  • eBook ISBN: 978-1-59259-743-7Published: 24 November 2003

  • Series ISSN: 2364-1134

  • Series E-ISSN: 2364-1142

  • Edition Number: 1

  • Number of Pages: XVII, 386

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation